Form 4 for ADMA ADMA BIOLOGICS, INC.
Accepted 2023-08-23 00:00:00 ET · period of report 2023-08-22 · accession 0001140361-23-041054 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-08-23 | 2023-08-22 | ADMA | Fong Bryant | Dir | S - Sale | $3.87 | -1.43M | 0 | -100% | -$5.55M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-22 | S | D | 1,433,304 | $3.87 | 0 | I See footnote | — | — | (F1) Reflects the weighted average price of sales on August 22, 2023. The shares were sold in multiple transactions at prices ranging from $3.81 to $3.99, inclusive. (F2) Represents shares sold by Biomark Capital Fund ("Biomark Capital"). Mr. Fong is a Managing Director and General Partner at Biomark Capital and may have been deemed the beneficial owner of such shares. |